Consider two fictional situations. One person brings a favorable biological age report but says that ordinary activities have become more difficult. Another brings an unfavorable score but has no new concern and wants to know whether the number requires treatment. These are educational examples, not patient histories.
Neither visit should be organized around congratulating or alarming the person. The report is one topic for discussion, not a substitute for finding out what is happening.
My proposed starting point is: “What were you hoping this test would help you understand?” That question distinguishes a specific concern from curiosity, a follow-up question from a marketing promise, and a decision from the wish to obtain a reassuring number.
Look for a trajectory, not a label
“Older” and “younger” are labels on a report. A clinical history needs a sequence: what the person could do previously, what is different now, when the change started, and what it means in daily life.
In the first fictional situation, the declining ability deserves attention even though the score appears favorable. In the second, the report deserves an explanation without inventing a disease that has not been established. The examples do not prescribe a diagnostic pathway; they show why the same kind of report can lead to different conversations.
Healthy aging, as framed by the World Health Organization, focuses on the abilities that support well-being and on the environment in which a person lives. That perspective is broader than a laboratory score and allows personal priorities to remain part of the assessment. [11]
Make the decision explicit
Before adding another test, I would organize the discussion around the unresolved question. Are we investigating a new difficulty, reviewing an established condition, considering prevention, or simply explaining an unfamiliar result?
A published association is not enough to answer all of those questions. Biomarker validation is specific to the measure and its intended use; clinical utility requires evidence relevant to the decision being made. [4]
This is why a test result should not automatically trigger the same supplement bundle or follow-up schedule for everyone. The proposed action needs its own explanation, including uncertainty and alternatives. A person should be able to ask what would change if they chose not to repeat the test.
Function and context belong in the conversation
Daily activities offer a concrete starting point: getting around, managing responsibilities, participating in relationships, and doing activities that matter. Discussion can also include sleep, eating patterns, exercise, medicines, supplements, recent events, and available support. This is an editorial framework for preparing a visit, not a validated checklist or a direction to order a fixed panel.
For older adults, the WHO's ICOPE guidance emphasizes person-centered assessment and care planning, including support needs. Its scope should not be silently extended into a universal screening program for every middle-aged adult. The useful principle here is coordinated care built around the individual, not a new label. [12]
A conversation about long-term health should leave room for the person to say, “This is the activity I am most concerned about losing,” or “This is the goal I would like us to work toward.” Those answers cannot be inferred from an age score.
What counts as evidence of progress?
The CALERIE epigenetic analysis provides a useful caution: the intervention did not affect every clock in the same way. An interesting biomarker finding is not a direct measurement of additional life expectancy. [6]
Clinical benefit and an intermediate signal are different categories of evidence. A marker used as a surrogate for benefit needs validation for that context; a change in the marker should not simply be renamed “better health.” [10]
In a follow-up visit, I would therefore ask for a record of the agreed questions and outcomes: what was addressed, what remains uncertain, and what changes the person has noticed. Repeating a test can be discussed when there is a reason, not because every report must begin a subscription to more reports.
A private one-page preparation note
Here is a suggested format for preparing your own questions. It is not a medical record template or a self-assessment score. Write a short description of what changed and when, the daily activity affected, and your main concern. Add the medicines and supplements you use and the dates of any reports you would like reviewed.
Finish with two sentences: “The decision I need help with is…” and “The ability or activity I most want to preserve is…” Bring the complete age-test report, including its method, rather than only its headline number.
After the conversation, use the same page to record what you understood, any agreed action, who is responsible for it, and the follow-up arrangement. Leaving an item as uncertain is more useful than filling the gap with a conclusion nobody has made.
Keep the person larger than the score
The editorial approach proposed here is neither anti-technology nor a promise that a careful visit can predict the future. It is a commitment to asking what information adds, where its limits lie, and whether a proposed action fits the person in front of us.
A good assessment does not end by assigning you a new birthday. It ends with a clearer understanding of your priorities and the next reasonable step.
Related reading
Knowledge library — Dr. Elias Tamer
Brain health after 40 — MERHI ONE
For educational updates, explore the MERHI ONE newsletter and select your preferred edition. Registration is optional and separate from any clinical service. Newsletter
Fictional examples and general educational content, not a diagnosis or individualized treatment plan. Dr. Elias Tamer Merhi Júnior is a physician registered in Brazil; this English-language article does not imply medical licensure or the provision of care in the United States.
References
[4] Moqri M, et al. Validation of biomarkers of aging. Nature Medicine. 2024;30:360–372. DOI: 10.1038/s41591-023-02784-9. Source. ↩
[6] Waziry R, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging. 2023;3:248–257. DOI: 10.1038/s43587-022-00357-y. Source. ↩
[10] U.S. Food and Drug Administration. FDA Facts: Biomarkers and Surrogate Endpoints. Official institutional webpage. Source. ↩
[11] World Health Organization. Ageing. Official topic page. Source. ↩
[12] World Health Organization. Integrated care for older people (ICOPE): guidance for person-centred assessment and pathways in primary care. 2nd ed. 2025. ISBN 9789240103726. Source. ↩